Page 6,411«..1020..6,4106,4116,4126,413..6,4206,430..»

Pharmacy Board: Planned Parenthood Can Dispense Drugs

Posted: Published on October 4th, 2012

Today the New Hampshire Board of Pharmacy renewed Planned Parenthoods license to distribute prescription drugs. The decision comes despite a complaint brought by a New Hampshire Pro-Life Group. New Hampshire Right to Life submitted a complaint last spring claiming that Planned Parenthood of Northern New England could not dispense prescription drugs without a contract with the state. Right to Lifes attorney, Michael Tierney points out one of Planned Parenthoods contracts with the state was not approved by the Executive Council earlier this year. Tierney: There was not sufficient guarantees that they werent going to be using the taxpayers money to support their abortion business. The Board of Pharmacy voted unanimously to renew the license, which Planned Parenthood spokesperson Jennifer Frizzell says affirms that the organization is fully compliant with the law. Michael Tierney, Right to Lifes lawyer, is running for Executive Council, and state spending on Planned Parenthood has been a key issue in that race. Read more from the original source: Pharmacy Board: Planned Parenthood Can Dispense Drugs … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy Board: Planned Parenthood Can Dispense Drugs

Omnicare Specialty Care Group's ACS to Provide Specialty Pharmacy Services for XTANDI®

Posted: Published on October 4th, 2012

ORLANDO, October 3, 2012 - Omnicare Specialty Care Group`s specialty pharmacy, Advanced Care Scripts (ACS), has been added to the limited distribution network for Astellas` XTANDI (enzalutamide). As part of the XTANDI network, ACS will provide access and reimbursement support to physicians and patients and assist eligible patients without insurance. XTANDI (enzalutamide) capsules are approved for use in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. ACS manages and dispenses specialty medications in multiple disease categories, including cancer, infectious diseases, auto-immune disorders, multiple sclerosis and hemophilia. Its expertise across both the specialty and long-term care channels enables it to provide comprehensive solutions for prescribers and patients. "The recent approval of XTANDI represents an important step forward to prolong the lives of patients with advanced prostate cancer who have received chemotherapy," said David Hileman, Senior Vice President of Omnicare Specialty Care Group. "We are excited to partner with Astellas to provide a new treatment option for this growing patient population for which there has been a significant unmet medical need." About Omnicare Specialty Care Group Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune 400 company and provider of comprehensive pharmaceutical services based in … Continue reading

Posted in Pharmacy | Comments Off on Omnicare Specialty Care Group's ACS to Provide Specialty Pharmacy Services for XTANDI®

Pharmacy suspends operations after meningitis outbreak

Posted: Published on October 4th, 2012

NASHVILLE, TN (WSMV) - A Massachusetts company that produced a medical compound linked to a multi-state outbreak of a rare form of meningitis has suspended operations, according to a statement from the company. The New England Compounding Center, of Waverly, MA, released a statement Wednesday about the outbreak: "New England Compounding Center (NECC) is working closely with the Massachusetts Department of Public Health, the Massachusetts Board of Pharmacy and other regulators to identify the source of infection in patients who received injections of methylprednisolone acetate. Upon notification of incidents of infection, NECC immediately initiated a voluntary recall of this product on Sept. 26. As part of this process, we have voluntarily suspended operations while we assist authorities in their investigation." There have been 18 cases reported in Tennessee and two deaths, in addition to at least eight cases and two deaths in four other states. The company sent shipments of methylprednisolone acetate, a lumbar epidural steroid medicine, to Saint Thomas Outpatient Neurosurgery Center in Nashville, Specialty Surgery Center in Crossville and PCA Pain Care Center in Oak Ridge. The Channel 4 I-Team has learned compounding pharmacies, such as this Massachusetts company, that make these type of drug mixtures are not … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy suspends operations after meningitis outbreak

Framingham pharmacy identified as possible source of fungal meningitis outbreak blamed for 4 deaths

Posted: Published on October 4th, 2012

By Kay Lazar and Carolyn Y. Johnson, Globe Staff A Framingham compounding pharmacy has been identified by state and federal health officials as the source of a medication being investigated as a possible cause of an unusual fungal meningitis outbreak that has sickened 26 patients in five states who received steroid injections. Four of the patients have died. The pharmacy, New England Compounding Center, recalled three lots of methylprednisolone on Sept. 26, according to the US Food and Drug Administration. Eighteen of the meningitis cases have been reported in Tennessee, and cases also have been reported in Virginia, Maryland, Florida, North Carolina. A Nashville outpatient neurosurgery clinic closed last month after patients got sick after receiving steroid injections in their backs for pain. Here is a statement released Wednesday night by the Massachusetts health department regarding the investigation: The Massachusetts Department of Public Health is collaborating with the CDC, FDA, and other state public health officials to identify the cause of an outbreak of more than 25 suspected cases of aspergillus (fungal) meningitis under investigation in Florida, Maryland, North Carolina, Tennessee and Virginia. The cause for this cluster of cases is not yet known. There are four products common to … Continue reading

Posted in Pharmacy | Comments Off on Framingham pharmacy identified as possible source of fungal meningitis outbreak blamed for 4 deaths

Sarepta Skyrockets on 48-Week Data

Posted: Published on October 3rd, 2012

By Brenton Flynn | More Articles October 3, 2012 | 87.4 meters. For Duchenne muscular dystrophy patients taking a 50 milligram dose of Sarepta Therapeutics' (Nasdaq: SRPT) eteplirsen for 48 weeks, that's how much longer the average patient walked during a six-minute walk test than a placebo group, which began taking the drug after 24 weeks. Not only did the 50mg group outperform placebo, but it showed an average 27.1 meter increase in distance walked over the treatment period -- an astonishing improvement over the 36-week data, which showed a 5.2 meter decline for the 50mg group. Not only did the walk test show a statistically significant benefit, but measures of dystrophin, a vital protein that protects muscle fibers, showed statistically significant increases in both the initial treatment and delayed treatment/placebo group. This is the kind of data that could merit an accelerated approval from the Food and Drug Administration. We'll have to wait to find out for sure, but shareholders are already piling in, bidding up shares by more than 110% in early morning trading. Foolish bottom lineOne thing's for sure: These results are revolutionary for the patients and families dealing with Duchenne. However, today's move could place the … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Skyrockets on 48-Week Data

Improved Stroke Care with Aquilion ONE Presented at ASHNR

Posted: Published on October 3rd, 2012

TUSTIN, Calif.--(BUSINESS WIRE)-- Dr. Ken Snyder, Assistant Professor of Neurosurgery, Radiology and Neurology at State University of NewYork at Buffalo, will discuss how his institution used the AquilionTM ONE from Toshiba America Medical Systems, Inc. to diagnose stroke during a Lunch & Learn Symposium titled Acute Stroke Triage Using Whole Brain CT Perfusion. The presentation will take place Thursday, October 4, at noon ET, at the American Society of Head and Neck Radiologys (ASHNR) annual meeting, October 3 7, in Miami Beach, Fla. Aquilion ONE acquires whole brain perfusion images, showing dynamic blood flow for better visualization and more accurate diagnoses, said Satrajit Mistra, senior director, CT Business Unit, Toshiba. The systems fast acquisition and whole-brain coverage enable clinicians to develop treatment plans quickly, which is critical in stroke situations. About Toshiba America Medical Systems, Inc. With headquarters in Tustin, Calif., Toshiba America Medical Systems (TAMS) markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, x-ray and vascular equipment, and coordinates clinical diagnostic imaging research for all modalities in the United States. For more information, visit the TAMS website at http://www.medical.toshiba.com. About Toshiba Medical Systems Corporation Toshiba Medical Systems Corporation is a leading worldwide provider of … Continue reading

Comments Off on Improved Stroke Care with Aquilion ONE Presented at ASHNR

New unit 'improves' stroke treatment

Posted: Published on October 3rd, 2012

New unit 'improves' stroke treatment 10:37am Wednesday 3rd October 2012 in News HEALTH officials have released figures which show a controversial new centralised stroke treatment unit has improved the treatment of acute patients. Since the new centralised unit was set up at the University Hospital of North Durham, in Durham City, in January, about 89 per cent of patients have been given a brain scan within 24 hours of arriving. Also, every patient who needed clotbusting drugs was given an infusion within an hour of arrival. The centralised unit replaced a two-centre approach to stroke treatment, with some patients being taken to the Durham hospital and others being taken to Darlington Memorial Hospital. With the Darlington acute stroke unit now closed, members of Darlington Borough Councils health and partnerships scrutiny committee asked for more information about the way the new service is working. At the last meeting of the committee in July, councillors voiced concerns that some patients from the Darlington area with suspected strokes were still being taken by ambulance to the Memorial Hospital. New statistics released by the hospital trust yesterday showed that between January and July this year 89 per cent of 530 confirmed stroke patients in … Continue reading

Comments Off on New unit 'improves' stroke treatment

NFL Pro Bowler E.J. Henderson Supports Amarantus Biosciences #C4CT Concussion Program

Posted: Published on October 3rd, 2012

SUNNYVALE, Calif., Oct. 3, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its unique proprietary anti-apoptotic therapeutic protein known as MANF, today announced the commitment by former Minnesota Vikings Pro Bowl linebacker E.J. Henderson to support the further development of Amarantus' TBI research collaboration with Banyan Biomarkers. Mr. Henderson will be working alongside NFL veterans Jack Brewer and Corey Chavous to raise awareness and broaden the support base for the Amarantus-Banyan research collaboration by utilizing the Coalition for Concussion Treatment (#C4CT) awareness campaign on Twitter, led by Brewer Sports International. "Concussions and their long-term side effects are a huge problem for NFL players and alumni," said Mr. Henderson. "I have been following Amarantus since they announced their collaboration with Banyan last November, and I was impressed with the initial success achieved this summer. As a result, I've decided to become actively involved with Amarantus in order to help bring their research to the forefront in the mainstream media. I believe these types of advances in scientific research can ultimately help current NFL players and NFL alumni who are at an unusually high … Continue reading

Posted in Parkinson's Treatment | Comments Off on NFL Pro Bowler E.J. Henderson Supports Amarantus Biosciences #C4CT Concussion Program

Campbell seeks help in addressing PTSD, TBI

Posted: Published on October 3rd, 2012

http://www.armytimes.com/news/2012/10/ap-fort-campbell-seeks-hlep-addressing-ptsd-tbi-100212/ By Kristin M. Hall - The Associated Press Posted : Tuesday Oct 2, 2012 20:26:54 EDT FORT CAMPBELL, Ky. Fort Campbell is reaching out to the medical community in Kentucky to help address the challenges of post-traumatic stress and traumatic brain injury among returning service members and veterans. Experts from the militarys top behavioral health and brain injury research agencies came to the Army installation on the Tennessee-Kentucky state line Tuesday to teach civilian behavioral health professionals about the militarys current research and treatments into the invisible wounds that have become prevalent among troops returning from Iraq and Afghanistan. The National Suicide Prevention Lifeline: 1-800-273-TALK (8255) Col. Paul R. Cordts, the commander of Blanchfield Army Community Hospital at Fort Campbell, Ky., noted that President Obama issued an executive order in August that directed ways to improve mental health care for troops within the military and veterans under the Department of Veterans Affairs. We cannot do this alone on Fort Campbell, Cordts said. We depend on the community and we need your help in addressing these issues, especially around our mental health services. Faced with rising suicide rates, the Army and Fort Campbell held suicide prevention and awareness training for … Continue reading

Posted in Brain Injury Treatment | Comments Off on Campbell seeks help in addressing PTSD, TBI

Infertility treatments may significantly increase multiple sclerosis activity

Posted: Published on October 3rd, 2012

ScienceDaily (Oct. 3, 2012) Researchers in Argentina report that women with multiple sclerosis (MS) who undergo assisted reproduction technology (ART) infertility treatment are at risk for increased disease activity. Study findings published in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggest reproductive hormones contribute to regulation of immune responses in autoimmune diseases such as MS. According to a 2006 report from the World Health Organization (WHO), MS affects 2.5 million individuals worldwide and is more common among women than men. While previous research found that up to 20% of couples in Western countries experience infertility, women with MS typically do not have diminished fertility except in those treated with cyclophosphamide or high-dose corticosteroids. Medical evidence shows sex hormones and those involved in ovulation (gonadotrophin-releasing hormone (GnRH)) play an important role in the development of autoimmune disorders. "When MS and infertility coincide, patients seek ART to achieve pregnancy," explains Dr. Jorge Correale with the Ral Carrea Institute for Neurological Research in Buenos Aires. "Given the role of some reproductive hormones in autoimmune diseases, those with MS receiving infertility treatments are at particular risk of exacerbating their disease." To further understand the impact of infertility … Continue reading

Posted in MS Treatment | Comments Off on Infertility treatments may significantly increase multiple sclerosis activity

Page 6,411«..1020..6,4106,4116,4126,413..6,4206,430..»